VOLUNTARY ANNOUNCEMENT

VOLUNTARY ANNOUNCEMENT

PRODUCT LICENSING COOPERATION REGARDING THE RECOMBINANT HPV 9-VALENT VACCINE REC603 ESTABLISHED BETWEEN THE COMPANY AND INDIA’S BIOLOGICAL E COMPANY

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the“Company”together with its subsidiaries, the“Group”) on voluntary basis.

The board of directors of the Company (the“Board”) is pleased to announce that the Company has entered into a product licensing cooperation agreement (the“Agreement) with the renowned Indian biopharmaceutical company Biological E (“BE Company”) recently regarding the recombinant HPV 9-valent vaccine REC603. The Company will license the vaccine formulation, filling and packaging technologies to BE Company, and further license the drug substance production technology at an appropriate time. Pursuant to the Agreement, BE Company is granted an exclusive license to develop, manufacture, and commercialize the recombinant HPV 9-valent vaccine in India and in the tender markets led by the United Nations International Children’s Emergency Fund (UNICEF) and the Pan American Health Organization (PAHO). At present, the Company has received the upfront payment for this cooperation and will receive milestone payments based on the progress of the cooperation, as well as royalties calculated at a certain percentage of the annual net sales.

It is reported that India has a population of approximately 1.44 billion, with about 23 million newborns each year, demonstrating enormous market potential for HPV vaccines. Founded in 1953, BE Company is India’s first private biopharmaceutical enterprise, boasting rich experience in vaccine R&D, manufacturing, and commercialization, and serving as an important partner of UNICEF and PAHO. This strategic cooperation with BE Company marks another significant milestone for the Company in actively expanding into the Indian and broader international markets.

Headquartered in Hyderabad, India, BE Company is a pharmaceutical and biopharmaceutical enterprise. BE Company is dedicated to the development, production, and supply of vaccines and therapeutic drugs. Its vaccine products are supplied to more than 140 countries globally, while its therapeutic products are marketed in the Indian, US, and European markets. At present, BE Company’s product portfolio includes 10 vaccines approved by the World Health Organization (WHO) and 10 generic injectables approved by the US Food and Drug Administration (USFDA).

Cervical cancer ranks as the fourth leading cause of cancer-related deaths among women worldwide. The HPV 9-valent vaccine can prevent approximately 90% of cervical cancer, anal cancer, and genital warts, making it the most effective HPV vaccine currently available in the market. As the core product of the Company, the recombinant HPV 9-valent vaccine REC603 is indicated for individuals aged 9 to 45 and is currently in the critical follow-up phase of Phase III clinical trials in China.

Shareholders and potential investors of the Company should note that the Group may not develop or market the recombinant HPV 9-valent vaccine REC603 successfully and should exercise caution when dealing in the securities of the Company.

By order of the Board

Jiangsu Recbio Technology Co., Ltd.

Dr. LIU Yong

Chairman

Jiangsu Province, the PRC, June 30, 2025

* Recbio is one of the member of China Association for Vaccines